Protalix BioTherapeutics (PLX) Stock: Gaining On Strong Earnings


Protalix BioTherapeutics (NYSEMKT: PLX) is off to an incredibly strong start to the trading session today, and for good reason. The company reported earnings for the first quarter, coming in ahead of expectations on both the top and bottom line. This led to excitement among investors, causing gains in the value of the stock and prompting our partners at Trade Ideas to send an alert. At the moment (9:30), PLX is trading at $0.96 per share after a gain of $0.04 per share or 4.45% thus far today.

PLX Reports Q1 Earnings

As mentioned above, Protalix Biotherapeutics is off to a strong start to the trading session today after reporting earnings for the first quarter that were ahead of expectations. In terms of earnings per share, the company produced a loss of $0.07 per share, beating analyst expectations by $0.02. On the revenue side of the equation, the company showed incredible growth. During the quarter, PLX generated revenue of $2.89 million, beating analyst expectations by $0.34 million and representing year over year growth in the amount of 325%. In a statement Moshe Manor, President and CEO at PLX had the following to offer…

This quarter we remained focused on driving our lead clinical asset pegunigalsidase alfa through clinical development including FDA clearance of our IND for the first ever once monthly dose of pegunigalsidase alfa. This will further differentiate pegunigalsidase and its potential superiority to currently available therapies. We also announced very strong, positive results for alidornase alfa from our Phase II study in Cystic Fibrosis… Additionally, in the first quarter we recorded increased revenue from sales of alfataliglicerase in Brazil and we anticipate revenues will further increase significantly throughout the year.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on PLX. In particular, we’re interested in following the ongoing development of both pegunigalsidase alfa and alidornase alfa as both treatments seem to be overwhelmingly promising. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

Previous articleMannKind (MNKD) Stock: Flying Ahead Of Earnings
Next articleNVIDIA (NVDA) Stock: Gaining Big On Strong Earnings
Hey, Im Joshua, the founder of CNA Finance. I enjoy following the trends in the market and finding the catalysts that are making the moves. If you want to get in contact with me, leave a comment below or email me at Please keep in mind that I am not an investment advisor and nor is CNA Finance. This is a news and information gathering outlet. We may work directly with some of the companies that we write about. If we have a business relationship with an issuer, we will mention that in the articles. We also have various affiliate relationships with advertisers and may be paid if you sign up for a service that you were referred to through our website.


Please enter your comment!
Please enter your name here